J&J Strengthens Diabetes Pipeline With Two Deals
This article was originally published in The Pink Sheet Daily
Executive SummaryA late-stage deal for a type 1 treatment and an early-stage deal for a series of type 2 compounds help J&J's move into diabetes, where it has traditionally been strong in blood glucose monitoring.
You may also be interested in...
A New Collaborative Model? Janssen Joins Evotec And Harvard To Advance Regenerative Diabetes Projects
Germany's drug discovery services company Evotec has formed a tight bond with Harvard researchers, with both parties expected to share the rewards of their CureBeta pancreatic beta-cell regeneration project if new strategic partner Janssen Pharmaceuticals develops new diabetes therapies from their research.